Shares of Amarin (AMRN) Plunge as USPTO Issues Non-Final Rejection for 13/284,408 Patent
Down)
Amarin (Nasdaq: AMRN) shares are nosediving Wednesday afternoon as bulls were not able to take the price back over the 200-day SMA. Shares last traded at $8.03, down more than 8 percent from Tuesday's close.
Minutes ahead of the decline, the USPTO disclosed a non-final rejection on Amarin's 13/284,408 patent.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Minutes ahead of the decline, the USPTO disclosed a non-final rejection on Amarin's 13/284,408 patent.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Data for Amarin's AMR101 to be Presented at the National Lipid Association 2012 Annual Scientific Sessions
- Rosetta Genomics (ROSG) Names New CFO
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
Create E-mail Alert Related Categories
Corporate News, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
